CD274 and hepatocellular carcinoma: Given the promising results from the initial attempts with ICIs in HCC, different mAb targeting PD1/PDL1 have been developed and approved by the U.S. FDA for the treatment of patients with advanced HCC, and a number of combination strategies have been considered and tested in current clinical trials [47,48,49,50,51].